DI-UMONS : Dépôt institutionnel de l’université de Mons

Recherche transversale
Rechercher
(titres de publication, de périodique et noms de colloque inclus)
2013-05-13 - Colloque/Présentation - communication orale - Allemand - 10 page(s)

Colet Jean-Marie , "Metabonomics in Drug risk Assessment" in 1st Belgium-Netherlands Metabolomics Symposium, Spa, Belgique, 2013

  • Codes CREF : Biologie (DI3100)
  • Unités de recherche UMONS : Biologie humaine et Toxicologie (M125)
  • Instituts UMONS : Institut des Sciences et Technologies de la Santé (Santé)
Texte intégral :

Abstract(s) :

(Anglais) Metabonomics in drug risk assessment J.-M. Colet Department of Human Biology & Toxicology / UMons In the last decade, the metabonomics approach has been extensively applied in the pharmaceutical industry in order to accelerate drug development. Most of the efforts have been made to the field of toxicology. In particular, the COMET (Consortium on Metabonomics in Toxicology) project systematically evaluated the effects of 150 prototypical drugs on the urinary and plasma metabonomic profiles of rodents. The goal was to develop predictive tools able to rapidly screen new drugs for their potential adverse effects. The methodology included single dose study in rats and mice, collection of 24-hr urine samples for 7 days, collection of plasma samples, histopathology, and clinical chemistry. In parallel, the NMR-based metabonomics profiles were also analyzed under various normal physiological conditions to discriminate “normal” from “toxic” related effects. Hence, the effects of inter-animal and diurnal variation, gender, age, diet, species, strain, hormonal status and stress on the biochemical composition of urine were explored.